drugset
drugset / Trial / NCT03516071

A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC

NCT03516071 ↗

Phase 2 Completed 90 enrolled Zai Lab (Shanghai) Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase 2, Open-label, Randomized, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Brivanib in Patients with Previously Treated Advanced Hepatocellular Carcinoma.

Timeline

Start
2017-05-17
Primary completion
2018-11-09
Completion
2019-07-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Brivanib Small molecule 400 mg Oral
Subject Brivanib Small molecule 800 mg Oral

Indications

hepatocellular carcinoma